Pfizer (PFE) said Friday that its pivotal phase 3 trial evaluating sasanlimab in combination with Bacillus Calmette-Guerin, or BCG, as treatment for non-muscle invasive bladder cancer achieved its primary endpoint of event-free survival.
The study showed that the combination therapy provided a "clinically meaningful and statistically significant improvement" compared with BCG alone, according to Pfizer.
Prolonged event-free survival provided by the investigational treatment may delay or reduce the need for more aggressive treatment options, said Neal Shore, lead investigator for the trial.
The safety profile of sasanlimab in combination with BCG "was generally consistent" with the known profiles of BCG and PD-1 inhibitors, Pfizer added.
The company said sasanlimab is also being investigated in combination with its antibody drug conjugate portfolio in advanced solid tumors.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。